Rodney Prell - Senior Fellow (Dev Sci), Safety Assessment

Rodney Prell

Senior Fellow (Dev Sci), Safety Assessment

"It has been a privilege to work in Safety Assessment at Genentech, where we take patient safety as our highest priority."
Years at Genentech
Publications at Genentech

I received my PhD and postdoctoral training in immunotoxicology and cancer immunotherapy, respectively. I joined Genentech as a scientist/toxicologist in 2007 after six years of cancer immunotherapy pharmacology and toxicology research in small biotech in the San Francisco Bay Area. My initial responsibilities were mainly as a project team toxicologist where I designed and implemented non-clinical safety studies to support INDs through BLAs. I am currently a Staff Scientist/Toxicologist and Safety Assessment Therapeutic Area Lead for Cancer Immunology, where I have oversight for the safety assessment strategy for the Cancer Immunology portfolio. I am a Diplomat of the American Board of Toxicology (DABT) since 2004.

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Int J Toxicol 2016 35(3): 263-273.

Prell, R.A., Halpern W.G. and Rao, G.